Foresight Diagnostics

Foresight Diagnostics Company Overview

Foresight Diagnostics, founded in 2020 and headquartered in Boulder, Colorado, is a privately held CLIA-registered cancer diagnostics company. The company focuses on developing ultra-sensitive liquid biopsy assays for minimal residual disease (MRD) detection across solid tumors and hematologic cancers. Its flagship platform, Foresight CLARITY™, achieves detection limits at parts-per-million sensitivity and is set for commercial launch in 2026.

Core Business and Key Technologies

Foresight Diagnostics specializes in next-generation sequencing (NGS)-based MRD testing. Proprietary innovations include:

• PhasED-Seq™ – a phased variant calling method providing unmatched sensitivity for circulating tumor DNA (ctDNA) detection.

• Foresight CLARITY™ – a scalable liquid biopsy assay capable of quantifying MRD at or below 1 part per million.

• Kit-based IVD development – in collaboration with QIAGEN, a regulated diagnostic kit is being designed to enable global clinical adoption.

Market Position and Flagship Product

Foresight CLARITY™ is emerging as the most sensitive ctDNA-MRD assay under development for lymphoma. Key validation and growth highlights include:

• DLBCL clinical validation – a prospective, multi-center study across 50+ sites in the Netherlands and Belgium demonstrated MRD-positive patients had 2-year progression-free survival (PFS) of 28% compared to 88% for MRD-negative patients, confirming MRD as an independent prognostic marker.

• Guideline integration – ctDNA-MRD testing is now Included in B-cell lymphoma treatment guidelines, supporting adoption in clinical practice.

• Strategic partnerships – collaborations with Allogene Therapeutics (ALPHA3 pivotal trial) and QIAGEN (global IVD/CDx kit development) reinforce the platform’s market potential.

Contact Information

Address: 2860 Wilderness Place, Suite 100, Boulder, CO 80301, USA

Phone: +1 720 449 2750

Email: press@foresight-dx.com